Home/Pipeline/NPT520-34

NPT520-34

Amyotrophic Lateral Sclerosis (ALS)

Pre-clinical/Phase 1Partnered (Biogen), Active

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Pre-clinical/Phase 1

Status

Partnered (Biogen), Active

Company

Neuropore Therapies

About Neuropore Therapies

Neuropore Therapies is a private biotechnology company pioneering a novel approach to treating neurodegenerative diseases by targeting the toxic protein aggregates that drive conditions like Parkinson's and ALS. The company's platform is built on a deep understanding of protein misfolding and cell-to-cell transmission of pathology, leading to a pipeline of orally available small molecules. While historically advancing programs into clinical trials, Neuropore has strategically partnered key assets and appears to be operating in a focused, non-commercial stage. Its long-term success hinges on clinical validation of its unique mechanism and the ability to secure further development funding or partnerships.

View full company profile

Therapeutic Areas

Parkinson's Disease Amyotrophic Lateral Sclerosis Neurodegenerative Diseases

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active
NG CELL	NeuroGenesis Bio	Phase 2	Active